SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir Technologies is trending heavily as traders debate the impact of an unexpected public endorsement from President Trump following a significant recent sell-off. While the community is sharply divided between those calling for a short squeeze fueled by institutional accumulation and skeptics echoing Michael Burry's warnings about valuation and competition, the stock remains a major focus due to its critical role in defense-tech infrastructure.

Lightwave Logic, Inc. is a development stage company which engages in the commercialization of electro-optic photonic devices. The firm offers the P2ICTM technology platform which uses in-house proprietary organic polymers. Its products include electro-optical modulation devices and proprietary polymer photonic integrated circuits. The company was founded on June 24, 1997 and is headquartered in Englewood, CO.

Lightwave Logic Inc

Lightwave Logic is currently seeing intense retail and institutional interest as investors bet on its electro-optic polymer technology to solve data center bottlenecks in the AI infrastructure cycle. The community remains deeply divided, with bulls pointing to recent foundry integration partnerships and the potential for a major industry acquisition, while skeptics warn of pre-revenue risks and argue the current valuation is driven by speculative hype rather than fundamental milestones.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is attracting significant investor attention as it progresses through multiple clinical catalysts, including upcoming trial updates for pancreatic and skin cancer. The community remains highly bullish, frequently pointing to strong institutional accumulation, a robust cash position without debt, and multiple analyst price target increases as reasons to accumulate shares before upcoming data readouts.

The Goldman Sachs Group, Inc. engages in the provision of financial services. It operates through the following business segments: Global Banking and Markets, Asset and Wealth Management, and Platform Solutions. The Global Banking and Markets segment includes investment banking, global investments, and equity and debt investments. The Asset and Wealth Management segment relates to the direct-to-consumer banking business which includes lending, deposit-taking, and investing. The Platform Solutions segment includes consumer platforms such as partnerships offering credit cards and point-of-sale financing, and transaction banking. The company was founded by Marcus Goldman in 1869 and is headquartered in New York, NY.

Goldman Sachs Group, Inc.

Goldman Sachs is seeing heightened attention following strong earnings results that highlighted robust performance in equities trading and investment banking. Market participants are actively discussing the bank's ability to navigate current market volatility, while debates continue regarding the broader financial sector's valuation and the impact of geopolitical and macroeconomic pressures on bank capital quality.

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is experiencing extreme volatility and intense community debate as the token surges on rumors of high-profile integrations and its expansion into Web3 entertainment. While some traders are celebrating massive gains and pointing to upcoming global event partnerships as long-term catalysts, others remain deeply skeptical, frequently labeling the project a speculative pump-and-dump scheme.

Aeluma, Inc. engages in developing semiconductors for sensing, communication, and computing applications. The firm is also involved in manufacturing devices using compound semiconductor materials on large-diameter substrates that are commonly used to manufacture mass market microelectronics. The company was founded by Jonathan Klamkin and Lee McCarthy on February 28, 2019 and is headquartered in Goleta, CA.

Aeluma Inc

Aeluma Inc. is trending following contract awards from the U.S. government for quantum materials and high-speed datacom, signaling a potential shift toward commercialization that has sparked intense debate among investors. The community is sharply divided, with bulls pointing to the company's proprietary III-V-on-silicon platform and low-float potential, while vocal criticsciting lack of foundry partnerships and limited revenueare actively challenging the company's valuation and long-term viability.

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ and GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

Ideaya Biosciences Inc

Ideaya Biosciences is surging following positive topline results from the Phase 2/3 OptimUM-02 trial, where the darovasertib-crizotinib combination significantly improved median progression-free survival in patients with first-line metastatic uveal melanoma. Investors and the biotech community are actively discussing this success as a major de-risking event that positions the company for an accelerated FDA filing and potential transition into a commercial-stage organization.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix is trending as investors digest detailed Phase 3 data for Axpaxli, with clinical presentations at the Macula Society and investor webcasts fueling intense speculation regarding a potential regulatory path or acquisition. While the community is debating the clinical nuances of the trial results, sentiment is buoyed by heavy institutional interest and the stock's recovery from recent volatility as participants position themselves ahead of further updates.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

Applied Optoelectronics is experiencing extreme volatility driven by a major follow-on order for its 800G optical transceivers and intensifying speculation surrounding its role in hyperscale data center infrastructure. While the community is actively debating the company's valuation and reliance on a single key customer, bulls point to a massive production pipeline and long-term capacity expansion as structural catalysts for growth.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is seeing significant momentum driven by a series of high-profile partnerships, including expanded collaborations with Google on server CPUs and involvement in Tesla and SpaceX's Terafab project. The community is actively debating whether this rapid rally indicates a genuine structural turnaround for the legacy chipmaker or a speculative bubble, with many traders closely monitoring institutional sentiment and key technical breakout levels.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The private placement, worth $4 million, is expected to close around April 7th.&nbsp;</li><li>Focus Universal said that the offering consisted of the sale of about 1.12 million common units, each comprising either a share or a pre-funded warrant, plus Series A and Series B warrants to buy shares at $3.33.&nbsp;</li><li>The company said that it expects to use the net proceeds from the offering for general corporate purposes and working capital.</li></ul>Shares of Nevada-based Focus Universal Inc. (FCUV) rallied more than 67% on Monday after the company announced a private placement worth $4 million.Focus Universal, which provides patented hardware and software design technologies, said that it had entered into definitive agreements with institutional investors for the private placement of its common stock and pre-funded and investor warrants at a price of $3.58 per share.The transaction is expected to close around April 7, the company said.<h2 class="st-heading-2">Private Placement Details</h2>Focus Universal said that the offering consisted of the sale of about 1.12 million common units, each comprising either a share or pre-funded warrant, plus Series A and Series B warrants to buy shares at $3.33.Each unit was priced at $3.58, or at about $3.579 for pre-funded units, equal to the offering price per common share minus an exercise price of $0.00001 per pre-funded warrant.The company said that the pre-funded warrants are immediately exercisable with no expiry. Series A warrants, with an initial exercise price of $3.33 per share would also be exercisable immediately and expire in 24 months, while Series B warrants will expire in 60 months. Each pre-funded unit replaces one common unit in the offering structure.Focus Universal said that it expects to use the net proceeds from the offering for general corporate purposes and working capital.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around FCUV shares jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours.Meanwhile, message volumes surged from ‘low’ to ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/FCUV">FCUV stock</a> has lost about 36% so far this year.Meanwhile, <a href="https://stocktwits.com/symbol/IWC">iShares Micro-Cap ETF</a> (IWC), which tracks micro-capitalization U.S. companies, has risen about 3.25% in the same time.Also Read: <a href="https://stocktwits.com/news-articles/markets/equity/plug-stock-rises-most-in-a-month-retail-turns-bullish-on-hydrogen-deal/cZJ4HG3RIYm">PLUG Stock Rises Most In A Month — Retail Turns Bullish On Hydrogen Deal</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Is FCUV Stock Surging More Than 67% Today?

Nevada-based Focus Universal on Monday announced that it had entered into definitive agreements with institutional investors for the private placement of its common stock, and pre-funded and investor warrants. 

This Micro-Cap Tech Stock Surged More Than 67% Today — Here’s Why

Equity

<ul class="summary-bullets"><li>The company stated that it intends to use the proceeds of the stock offering to meet its working capital requirements as well as other general corporate needs.</li><li>Last week, Outlook Therapeutics announced a new $18.4 million non-convertible unsecured note financing, stating that it will use a portion of the net proceeds to pay down an existing note.</li><li>In December 2025, the FDA issued a Complete Response Letter for ONS-5010 / LYTENAVA, saying it could not approve the treatment in its current form for wet AMD.</li></ul>Outlook Therapeutics Inc. (OTLK) shares plunged 32% in Tuesday’s pre-market trade after the company announced a proposed public offering of its common stock and accompanying warrants.Outlook Therapeutics announced the pricing of the public offering, stating that each share of common stock and the accompanying warrant are being sold at a combined price of $0.25. The company said it expects aggregate gross proceeds of $5 million and that the offering is expected to close on Wednesday, March 25, 2026.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/OTLK">Outlook Therapeutics</a> trended in the ‘extremely bearish’ territory, with message volumes at ‘high’ levels at the time of writing.<h2 class="st-heading-2">Why Did Outlook Therapeutics Announce The Offering?</h2>Outlook Therapeutics stated that it intends to use the proceeds of the stock offering to meet its working capital requirements as well as other general corporate needs.Last week, the company announced a new $18.4 million non-convertible unsecured note financing, stating that it will use a portion of the net proceeds to pay down an existing note.Earlier this month, Outlook Therapeutics provided an update with respect to a meeting with the U.S. Food and Drug Administration (FDA) regarding the company’s Biologics License Application for its treatment of wet age-related macular degeneration (wet AMD).In December 2025, the company said that the FDA issued a Complete Response Letter for its investigational treatment, ONS-5010 / LYTENAVA (bevacizumab-vikg), stating that it cannot approve the application in its present form for the treatment of wet AMD.The company said that if the FDA approves it, bevacizumab-vikg has the potential to be the first ophthalmic formulation of bevacizumab-vikg approved by the regulator for use in ophthalmology.Bevacizumab-vikg is a lab-made antibody that targets a protein called VEGF, which helps blood vessels grow. By blocking VEGF from binding to its receptors on blood vessel cells, the drug prevents the formation of new blood vessels.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Outlook Therapeutics’ proposed offering was&nbsp;criticized&nbsp;by a user on the platform, who called out the company for not giving a roadmap on how it intends to use the money, other than meeting its working capital and general corporate needs.<stembedurl>https://stocktwits.com/HarveySpecter20/message/648356634</stembedurl>Another user highlighted the lack of data on the uptake of the investigational treatment from patients.<stembedurl>https://stocktwits.com/updownsides/message/648355300</stembedurl><a href="https://stocktwits.com/symbol/OTLK">OTLK stock</a> is down 80% year-to-date and 79% over the past 12 months. The Vanguard Extended Market Index Fund ETF (VXF) is up 16% over the past 12 months, while the iShares Micro-Cap ETF (IWC) is up 38%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/fidelity-backs-elon-musk-tesla-spacex-terafab-project-datacenters-in-space/cZ3mK7PRI0u">Elon Musk's Joint Tesla, SpaceX Terafab Project Makes A 'Ton Of Sense', Says Investor Fidelity: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Trading digital board showing the data on global stock market crash. | Image source: Getty Images

Why Is OTLK Stock Falling Today?

Outlook Therapeutics announced the pricing of the public offering, stating that each share of common stock and the accompanying warrant are being sold at a combined price of $0.25.

<ul class="summary-bullets"><li>Apollo intends to stick to the same cap next quarter as it balances “the interests of shareholders seeking liquidity with those who choose to remain invested,” per the letter.&nbsp;</li><li>The firm expects the granted redemptions to amount to roughly $730 million of gross outflows for the first quarter.</li><li>Apollo Debt Solutions is returning less cash to clients than some of its peers that capped withdrawals, the report said.&nbsp;&nbsp;</li></ul>Apollo Global Management is reportedly curbing redemptions from one of its largest non-traded private credit funds for retail investors, sending shares down nearly 3% in extended hours of trading.&nbsp;The $25 billion business development company, Apollo Debt Solutions, capped withdrawals at 5% of outstanding shares Monday after clients sought to redeem 11.2%, according to a report from Bloomberg News that cited a shareholder letter.&nbsp;<h2 class="st-heading-2">Details</h2>With redeeming investors receiving just 45% of their capital, Apollo Debt Solutions is returning less cash to clients than some of its peers that capped withdrawals, the report said.&nbsp;&nbsp;Apollo intends to stick to the same cap next quarter as it balances “the interests of shareholders seeking liquidity with those who choose to remain invested,” per the letter. Apollo, which has been pushing for more transparency in private markets, reportedly said that Apollo Debt Solutions had returned 1% over the past three months.&nbsp;The firm expects the granted redemptions to amount to roughly $730 million of gross outflows for the first quarter, offsetting the roughly $724 million of inflows for the period, the report said.&nbsp;<h2 class="st-heading-2">Private Sector Reeling</h2>The private credit industry has been seeing a rise in redemption rates across several funds over fears about the asset class, as well as its exposure to software businesses, which are at risk of AI-related disruption.Blue Owl earlier said that it will permanently stop allowing redemptions from Blue Owl Capital Corp. II, a semi-liquid private credit fund marketed to U.S. retail investors.Blackstone’s $82 billion Blackstone Private Credit Fund (BCRED) disclosed a rise in redemption rates. BCRED’s first-quarter (Q1) redemption requests totaled 7.9% of the outstanding shares, up from 4.5% in Q4.&nbsp;<h2 class="st-heading-2">Retail reaction</h2>Retail sentiment around APO trended in ‘bearish’ territory amid ‘normal’ message volume.&nbsp;Shares in the company have fallen 24% so far in 2026.&nbsp;

 In this photo illustration, the Apollo Global Management company logo is seen displayed on a smartphone screen.

Apollo Reportedly Caps Private Credit Fund Withdrawals; Stock Dives

The $25 billion business development company, Apollo Debt Solutions, capped withdrawals at 5% of outstanding shares Monday after clients sought to redeem 11.2%, according to a report from Bloomberg News. 

<ul class="summary-bullets"><li>The company stated in its announcement that it intends to use the funds raised through this stock offering to acquire additional inventory, for working capital needs, and for general corporate purposes.</li><li>Donald Trump Jr., who is on the company’s advisory board, said that the latest capital infusion will enable Unusual Machines to build the foundation for a strong domestic drone industry.</li><li>The Florida-based company announced a public offering on Thursday to expand its U.S. drone parts inventory and for working capital and general corporate purposes.</li></ul>Unusual Machines Inc. (UMAC) on Friday announced the pricing of its public offering to raise $150 million, which includes a strategic investment from Ondas Inc. (ONDS).Unusual Machines stated that it will issue 8.8 million shares at $17 apiece, a discount of more than 9% to the stock’s closing price on Thursday.<a href="https://stocktwits.com/symbol/UMAC">Unusual Machines shares</a> were down more than 13% in Friday’s opening trade. Retail sentiment on Stocktwits about the company trended in ‘bearish’ territory, while message volume was at ‘high’ levels at the time of writing.<h2 class="st-heading-2">What Will UMAC Use These Funds For?</h2>Unusual Machines stated in its announcement that it intends to use the funds raised through this stock offering to acquire additional inventory, for working capital needs, and for general corporate purposes.“We approach capital the same way we approach operations, deliberately and with a clear plan for deployment. This raise allows us to expand inventory, support production, and continue building a reliable, U.S.-based supply chain for drone components,” said Unusual Machines CEO Allan Evans.President Donald Trump’s son, Donald Trump Jr., who is on the company’s advisory board, said that the latest capital infusion will enable Unusual Machines to build the foundation for a strong domestic drone industry.<h2 class="st-heading-2">What Does Unusual Machines Do?</h2>Unusual Machines manufactures and sells drone components and drones. It also sells small acrobatic first-person-view (FPV) drones and equipment directly to consumers.The Florida-based company announced a public offering on Thursday to expand its U.S. drone parts inventory and for working capital and general corporate purposes.<a href="https://stocktwits.com/symbol/UMAC">UMAC stock</a> is up 127% year-to-date, while ONDS stock is up 4%. The SPDR S&amp;P Kensho New Economies Composite ETF (KOMP) is up 23% over the past 12 months, while the iShares Micro-Cap ETF (IWC) is up 35%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/fedex-beat-and-raise-q3-wall-street-price-target-hikes-for-fdx-stock/cZ3Xqp2RILh">FedEx's Beat And Raise Q3 Earns Street Accolades As Price Target Hikes Pour In — Analysts Flag 'Unique Combination' Of Price And Yield Growth</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Is UMAC Stock Falling Today?

Unusual Machines stated that it will issue 8.8 million shares at $17 apiece, a discount of more than 9% to the stock’s closing price on Thursday.

<ul class="summary-bullets"><li>Palladyne stated that the ALRRM is capable of exceeding a distance of 350 nautical miles at an unspecified but high altitude.</li><li>This missile can cover this distance at a sustained cruise speed of beyond the required Mach 4.0.</li><li>Palladyne also stated that the ALRRM can deliver a 150-lb warhead air-breathing solid-fuel ramjet.</li></ul>Palladyne AI Corp. (PDYN) on Wednesday announced that its subsidiary has been awarded a contract by the U.S. Navy to develop new air-launched, near-hypersonic, long-range, low-cost missiles.Palladyne’s subsidiary GuideTech will develop the new Air-Launched Rapid Response Missile (ALRRM). The company said that ALRRM is expected to deliver nearly hypersonic speed and long range at a fraction of the cost of other hypersonic weapons.<a href="https://stocktwits.com/symbol/PDYN">Palladyne AI shares</a> were up more than 15% in Wednesday’s pre-market trade. Retail sentiment on Stocktwits around the company trended in the ‘neutral’ territory. PDYN was the second most trending ticker on the platform at the time of writing.<h2 class="st-heading-2">What Is ALRRM Capable Of?</h2>Palladyne stated that the ALRRM is capable of exceeding a distance of 350 nautical miles at an unspecified but high altitude. This missile can cover this distance at a sustained cruise speed of beyond the required Mach 4.0. Palladyne also stated that the ALRRM can deliver a 150 lb warhead air-breathing solid fuel ramjet (SFRJ).“The 2025 National Security Strategy explicitly states that the U.S. must build ‘next-generation missiles with a clear and urgent need for cost-effective, high-performance strike capabilities’ for the U.S. military,” said Palladyne AI CEO Ben Wolff.Wolff added that the ALRRM can deliver on these strategic needs at a fraction of the cost.“We believe there is no other missile currently available to the U.S. military that combines the speed, range, and payload capacity of the ALRRM, at this size and price point — creating a new strike class for 5th gen fighters that is stealth-borne, near-hypersonic, and deep-theater strike,” he added.This comes amid the ongoing Iran war, with the U.S. having incurred over $11 billion in the first week of the conflict. The Trump administration could reportedly seek an additional funding of&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/peter-schiff-warns-debt-risk-trump-seeks-50b-for-iran-war/cZ3EEoORIXe">$50 billion</a> to replenish the weapons stockpile of the U.S.<h2 class="st-heading-2">What Does Palladyne AI Do?</h2>Palladyne AI is a Salt Lake City, Utah-based company developing AI and autonomy solutions, advanced avionics and more for the defense and industrial markets.Earlier this month, the company reported a loss of $0.16 per share on revenue of $1.66 million, while Wall Street expected a loss of $0.14 per share on revenue of $0.81 million, according to Fiscal.ai data.<a href="https://stocktwits.com/symbol/PDYN">PDYN stock</a> is up 59% year-to-date, but down 12% over the past 12 months. The iShares Micro-Cap ETF (IWC) is up 39% over the past 12 months, while the Themes Generative Artificial Intelligence ETF (WISE) is up 1%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/will-fed-consider-rate-hikes-strategist-warns-inflation-worse-amid-iran-war/cZ37Bn2RIgW">Will The Fed Consider Rate Hikes Again? Strategist Warns Inflation Picture Could 'Get A Lot Worse' Amid Iran War</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Palladyne AI Corp. logo is seen displayed on a smartphone screen. 

Palladyne AI Subsidiary Wins US Navy Contract For Developing New Missiles — PDYN Stock Soars Pre-Market

The company said that the Air-Launched Rapid Response Missile is expected to deliver nearly hypersonic speed and long range at a fraction of the cost of other hypersonic weapons.

<ul class="summary-bullets"><li>Greenwich noted that despite the absence of a placebo arm, GLSI-100 showed an annual recurrence rate below 1%, compared with about 4% in the KATHERINE trial of Kadcyla over a similar timeframe.</li><li>The company also stated that the Phase III trial results are trending in line with those from the Phase IIb trial.</li><li>Greenwich reported a reduction of up to 80% in breast cancer recurrences, while other approved products showed a reduction of 20% to 25%, the company said.</li></ul>Greenwich LifeSciences Inc. (GLSI) shares gained more than 13% in Tuesday’s pre-market trade after the company announced that its immunotherapy trial has shown a continued reduction in the rate of recurrence of breast cancer.Greenwich LifeSciences said its 250-patient Phase III breast cancer immunotherapy trial, FLAMINGO-01, showed an annual recurrence rate below 1%.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/GLSI">Greenwich LifeSciences</a> trended in the ‘extremely bullish’ territory with message volumes at ‘extremely high’ levels. GLSI was the top trending ticker on the platform at the time of writing.<h2 class="st-heading-2">Results Show About 70-80% Reduction In Recurrence Rate, Says Greenwich</h2>Greenwich noted that despite the absence of a placebo arm, GLSI-100 showed an annual recurrence rate below 1%, compared with about 4% in the KATHERINE trial of Kadcyla over a similar timeframe.The company also stated that the results of the Phase III trial are trending in line with those from the Phase IIb results. Greenwich reported a reduction of up to 80% in breast cancer recurrences, while other approved products showed a reduction of 20% to 25%, the company said.However, Greenwich stated that these Phase III trial results are still preliminary and that the final analysis may differ.The Phase III FLAMINGO-01 trial is designed to evaluate the safety and efficacy of GLSI-100 in HER2-positive breast cancer patients with residual disease or high-risk pathological complete response who have completed neoadjuvant and adjuvant trastuzumab-based therapy.<h2 class="st-heading-2">What Does Greenwich LifeSciences Do?</h2>Greenwich LifeSciences is a clinical-stage biopharmaceutical company based out of Stafford, Texas. It is currently focused on the development of GP2, which is an immunotherapy to prevent breast cancer recurrence in patients who have previously undergone surgery.<a href="https://stocktwits.com/symbol/GLSI">GLSI stock</a> is up 34% year-to-date and 134% over the past 12 months. The iShares Russell 2000 Growth ETF (IWO) is up 22% over the past 12 months, while the iShares Micro-Cap ETF (IWC) is up 40%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-says-fed-chair-powell-should-cut-rates-right-now/cZ3PPPaRIfw">Trump Says Fed Chair Powell Should Cut Rates Right Now</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Is GLSI Stock Rising Today?

Greenwich LifeSciences said its Phase III breast cancer immunotherapy trial, involving 250 patients, showed a recurrence rate of under 1% per year.

<ul class="summary-bullets"><li>The company said upon closing of the final transaction it will result in the cancellation of 1.34 million units of its publicly-traded senior notes across multiple outstanding series.</li><li>RILY said it repurchased 171,703 units of its 5.0% senior notes due 2026 (RILYG) for approximately $4.0 million in cash.</li></ul>BRC Group Holdings shares rallied more than 6% in extended hours of trading on Thursday after it announced a series of senior note transactions with an institutional investor, resulting in reduction of some of its debt.&nbsp;The company said that the closing of the final transaction will result in the cancellation of 1.34 million units of its publicly-traded senior notes across multiple outstanding series in exchange for the issuance of an aggregate of 4.2 million shares of its common stock at an average price of $7.0933 per share.<h2 class="st-heading-2">Details</h2>RILY said it repurchased 171,703 units of its 5.0% senior notes due 2026 (RILYG) for approximately $4.0 million in cash. Upon closing of the final transaction scheduled for March 13, 2026, the company's outstanding debt will be reduced by approximately $37.9 million."These senior note transactions, combined with continued appreciation in our investment portfolio, have further reduced our net debt position beyond the preliminary estimates communicated for December 31, 2025. We will continue to utilize multiple strategies to reduce debt and invest in our business,” said Bryant Riley, Chairman and Co-Chief Executive Officer of BRCGH.&nbsp;<h2 class="st-heading-2">10-K Report Expected This Month</h2>The company said that it expects to file its 2025 Annual Report on or before the extended deadline of March 31, 2026, and to announce the timing of its earnings release and earnings call next week."The Company values the enormous effort required by its team and business partners to file three Quarterly Reports on Form 10-Q between November 20, 2025 and January 14, 2026.&nbsp; Bringing these filings current while driving strong progress on our annual audit in an accelerated timeframe demonstrates the strength and resolve of our team — and positions us well for the road ahead. We look forward to discussing the Company and taking questions on the earnings call by the end of March,” Riley added.&nbsp;<h2 class="st-heading-2">Retail Reaction</h2>Retail sentiment around RILY trended in ‘extremely bullish’ territory amid ‘extremely high’ message volume.&nbsp;Shares in the company are up 52% so far in 2026.&nbsp;

RILY said it repurchased 171,703 units of its 5.0% senior notes due 2026 (RILYG) for approximately $4.0 million in cash. 

RILY Stock Rallies After-Hours – How Much Of Its Debt Is Reduced By Latest Senior Note Transactions?

The company said upon closing of the final transaction with an institutional investor its outstanding debt will be reduced by approximately $37.9 million.

<ul class="summary-bullets"><li>The revenue fell well short of analyst estimates of $144.95 million, according to data from Fiscal.ai.&nbsp;</li><li>The company said that its gross margin for Q4 was at 13.4%, compared to gross margin of 15.3% from year-ago.&nbsp;</li><li>The company said it expects FY 2026 revenue of $500 million to $550 million. However, it fell way short of Wall Street expectations of $625.65 million.&nbsp;</li></ul>FreightCar America shares slumped 19% during extended hours of trading on Monday as it reported a decline in its fourth quarter revenue.&nbsp;The company said its revenues in Q4 came at $125.6 million,&nbsp;lower than $137.7 million in the fourth quarter of 2024, despite railcar deliveries of 1,172 units compared to 1,019 units in the prior year period.&nbsp;The revenue fell well short of analyst estimates of $144.95 million, according to data from Fiscal.ai.&nbsp;<h2 class="st-heading-2">Q4 Snapshot</h2>The company posted a fall in its profit in Q4. It reported adjusted net income of $4.9 million, or $0.16 per share, compared to $0.21 per share from the year-ago quarter. RAIL also missed profit expectations of $0.19 per share, as per Fiscal.ai.&nbsp;“In 2025, FreightCar America executed with discipline amid a challenging industry environment, delivering revenue in line with our expectations while producing exceptional profitability,” said Nick Randall, President and Chief Executive Officer of FreightCar America.The company said that its gross margin was at 13.4% with gross profit of $16.8 million, compared to gross margin of 15.3% with gross profit of $21.0 million in the fourth quarter of 2024.&nbsp;<h2 class="st-heading-2">Outlook</h2>The company said it expects FY 2026 revenue of $500 million to $550 million. However, it fell way short of Wall Street expectations of $625.65 million.&nbsp;“As we enter 2026, we remain focused on converting backlog into profitable deliveries while continuing to invest for growth,” Randall said.&nbsp;“Looking ahead to 2026, our guidance reflects ongoing industry uncertainty while reinforcing our confidence in the underlying strength and resilience of the business,” said Mike Riordan, Chief Financial Officer of FreightCar America.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around RAIL trended in ‘bullish’ territory amid ‘high’ message volume.&nbsp;Shares in the company have fallen nearly 11% so far in 2026.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Freightcar Americs said its revenues in Q4 came at $125.6 million, lower than $137.7 million in the fourth quarter of 2024. 

FreightCar America Slumps 21% As Q4 Results And FY26 Disappoints Investors

The company said its revenues in Q4 came at $125.6 million, lower than $137.7 million in the fourth quarter of 2024, despite railcar deliveries of 1,172 units compared to 1,019 units in the prior year period. 

<ul class="summary-bullets"><li>AN2 Therapeutics is expected to sell more than eight million shares of common stock at $2.85 per share.</li><li>The private placement includes participation from institutional investors such as Coastlands Capital, Commodore Capital, and Vivo Capital.</li><li>The stock has gained more than&nbsp;500% over four sessions since the company announced positive results for its blood cancer treatment.</li></ul>Shares of AN2 Therapeutics (ANTX) surged more than 110% on Monday, after the clinical-stage biopharmaceutical company announced that it signed a securities purchase agreement for a private placement expected to raise about $40 million in gross proceeds.<a href="https://stocktwits.com/symbol/ANTX">ANTX shares</a> recorded their biggest-ever intraday gains.As part of the deal, AN2 Therapeutics will sell 8.25 million shares of common stock at $2.85 per share, which was also the stock’s closing price on Friday. The company also offered investors the option to purchase pre-funded warrants to acquire up to 5.79 million additional shares at nearly the same price, with an exercise price of&nbsp;$0.00001 per share.The private placement is expected to close on March 10, 2026, and includes participation from institutional investors such as Coastlands Capital, Commodore Capital, and Vivo Capital, along with other new and existing shareholders. AN2 Therapeutics did not disclose how it plans to use the proceeds from the offering.<h2 class="st-heading-2">500% Rally After Epetraborole Update</h2>The stock has been on an extraordinary rally, adding nearly 500% over four sessions since the company announced plans to further develop its drug epetraborole into a Phase 2 proof-of-concept study for patients with Polycythemia Vera (PV) who rely on phlebotomy treatments.PV is a blood cancer that causes the bone marrow to produce too many red blood cells, increasing the risk of serious complications such as blood clots.Last week, AN2 Therapeutics said that its oral epetraborole produced consistent and sustained reductions in hematocrit across several studies involving healthy volunteers and other patient groups. The company expects to begin the Phase 2 study in the third quarter of 2026 and plans to provide initial trial updates by the following quarter.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits remained ‘extremely bullish’ over the past 24 hours, amid ‘extremely high’ message volumes.<img src="https://news.stocktwits-cdn.com/ANTX_jpg_31ad151992.webp" alt="ANTX.jpg">One user highlighted the various resistance levels, speculating that the stock could climb as high as $108.<stembedurl>https://stocktwits.com/M105/message/647014265</stembedurl>However, another expressed confusion over the “bullish excitement.”<stembedurl>https://stocktwits.com/Tradeforlosses/message/647018987</stembedurl>Year-to-date, the stock has gained more than 400%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/iran-warns-of-crude-hitting-200-a-barrel-if-energy-infrastructure-is-targeted-report/cZdVpreRIIr">Iran Warns Of Crude Hitting $200 A Barrel If Energy Infrastructure Is Targeted: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

ANTX Stock Records Biggest Ever Single Day Gain, Surges 500% Over Past Four Sessions – What Triggered This Smashing Rally?

AN2 Therapeutics shares more than doubled in value on Monday after the company announced a private placement to raise about $40 million.

Tevogen CEO Ryan Saadi said in a letter to shareholders on Friday that the company is “actively evaluating” potential acquisitions to drive value.“If consummated, these transactions are expected to operate as subsidiaries of Tevogen resulting in positive cash flow generation and a return on invested capital over time,” the CEO said.As <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2026/03/06/3251264/0/en/Letter-to-Shareholders-from-CEO-Dr-Ryan-Saadi.html">per</a> the CEO, the combined entities under consideration for acquisition may generate aggregate annual revenues in excess of $50 million, based on preliminary evaluations.<h2 class="st-heading-2">Proposed Deals</h2>The CEO’s letter comes on the heels of the company announcing that it has entered into a letter of intent to evaluate a deal with another pharmaceutical company called Apozel Pharmaceuticals.If the deal with Apozel goes through, it could provide Tevogen with an established generics platform, the company had said. This includes 11 FDA-approved generic products for the U.S. market and others awaiting approval by the FDA or currently under development.Tevogen is also actively considering other transactions, the company said earlier this week, while expressing its interest in domestic generics, biosimilars, medical devices, and innovative insurance solutions for healthcare providers.Last month, the company signed another letter of intent to evaluate a deal with a global contract research organization.Earlier this week, the company also said that its Board has approved a reverse stock split of its common stock at a ratio of 50 for 1 to regain compliance with Nasdaq’s $1 minimum bid price requirement. The stock began trading on a split-adjusted basis on Friday.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around TVGN stock rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.<a href="https://stocktwits.com/symbol/TVGN">TVGN stock</a> has erased nearly 87% of its value over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/why-is-lnth-stock-up-after-hours/cZdLQ3SRI4B">Why Is LNTH Stock Up After Hours?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Tevogen CEO Says ‘Actively Evaluating’ Potential Acquisitions 

The announcement comes on the heels of the company announcing that it has entered into a letter of intent to evaluate a deal with another pharmaceutical company called Apozel Pharmaceuticals.

Current Price	$169.40
Prev Close	$170.24
Open	$170.61
Dividend Yield	N/A
50-Day Moving Average	$164.97
Beta	N/A
Avg. Volume	69,542.08
PE Ratio	N/A

52-Week High	$176.74
52-Week Low	$101.62
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

IWC
iShares Micro-Cap ETF

Feed

News

Sentiment

Fundamentals

Info

Latest IWC News

IWCiShares Micro-Cap ETF